Form 4 for MRNA Moderna
Accepted 2026-02-13 00:00:00 ET · period of report 2026-02-11 · accession 0001682852-26-000017 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-13 | 2026-02-11 | MRNA | Bancel Stephane | CEO, Dir | F - Tax | $41.99 | -5,450 | 6.19M | -0.1% | -$228.8K | |
| 2026-02-13 | 2026-02-11 | MRNA | Bancel Stephane | CEO, Dir | A - Grant | $0.00 | +11.3K | 6.19M | +0.2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-11 | F | D | 5,450 | $41.99 | 6,187,791 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-11 | A | A | 11,271 | $0.00 | 6,193,241 | D | — | — |